Life Science

Biodesix announced recently that the United States Patent and Trademark Office (USPTO) has awarded to the company patent number 7,736,905. The patent relates to the company’s first product Veristrat, which is used to identify non-small cell lung cancer patients likely to respond to therapy with erlotinib (Tarceva). Specifically, the patent is for the serum based identification of patients likely to benefit from epidermal growth factor targeted therapy. Instead of focusing on a single biomarker as many diagnostics do, Veristrat evaluates expected response based on many biomarkers measured via mass spectrometry and evaluated with proprietary algorithms. The patent additionally covers key aspects of the company’s ProTS platform, which has the potential to apply the same methods used in Veristrat to other types of medications and disease states. Biodesix is based in Broomfield, Colorado. RockyRadar recently reported on the company when Paul Beresford, the VP of business development, presented at a CBSA event.